Trump Launches Sweeping New Tariffs on Pharmaceuticals and Steel After Supreme Court Blocks IEEPA Authority
The Trump administration has executed a sweeping pivot in US trade policy, imposing a 100 percent duty on patented pharmaceuticals and new tariffs on steel, aluminum, and copper under Section 232 national security authority after the Supreme Court ruled in February 2026 that the International Emergency Economic Powers Act does not grant the president power to levy tariffs — a legal setback that forced the White House to rebuild its entire trade enforcement architecture from scratch.
Background
The Trump administration entered 2026 relying heavily on IEEPA as the legal foundation for its broad tariff agenda. The statute, passed in 1977, grants the president sweeping authority to regulate international commerce during a declared national emergency. The administration had used it to impose tariffs on dozens of trading partners, arguing that trade deficits and supply chain vulnerabilities constituted national emergencies.
On February 20, 2026, the Supreme Court ruled 6-3 that IEEPA's text does not encompass tariff authority, invalidating the legal basis for a significant portion of the administration's trade measures. The ruling forced an immediate policy scramble, with the White House invoking Section 122 of the 1974 Trade Act to impose a temporary 10 percent import surcharge while it developed a more durable legal strategy.
Key Developments
On April 2, 2026, President Trump signed an executive order imposing a 100 percent ad valorem duty on certain patented pharmaceuticals and their active ingredients, citing national security concerns under Section 232. The administration argued that US dependence on foreign-manufactured drugs — particularly from China and India — poses an unacceptable vulnerability to the national defense industrial base.
Simultaneously, new Section 232 tariffs ranging from 10 to 50 percent were imposed on imported steel, aluminum, and copper articles and their derivatives, expanding on the tariffs first imposed during Trump's first term. The US Trade Representative also launched dozens of new Section 301 investigations in March 2026, targeting the trade practices of approximately 60 countries including the European Union and China, focusing on forced labor practices and structural excess manufacturing capacity. These investigations could produce a new wave of country-specific tariffs across sectors from textiles to semiconductors.
The US trade deficit widened to $60.3 billion in March as importers rushed to front-run anticipated tariff increases, according to Commerce Department data released May 5. The ISM Services PMI's prices-paid component registered 70.7 in April, signaling that inflationary pressures from tariffs are flowing through to the services sector.
Why Americans Should Care
The pharmaceutical tariffs hit closest to home for the roughly 131 million Americans who take at least one prescription drug daily. Generic drug manufacturers, which produce about 90 percent of US prescriptions and rely heavily on active pharmaceutical ingredients from India and China, face cost increases that analysts project will translate into higher prices at pharmacies in every state. Patients in rural communities — particularly in Appalachia, the Mississippi Delta, and the rural Midwest — who already face limited pharmacy access are most exposed to supply disruptions.
For the steel and aluminum industries, the new Section 232 tariffs are a double-edged sword. Steelmakers in Pennsylvania, Ohio, and Indiana benefit from reduced foreign competition, but manufacturers in Michigan's auto sector and Texas's energy industry that use steel as an input face higher production costs. The Section 301 investigations targeting 60 countries add uncertainty for US exporters of agricultural products, particularly soybean farmers in Iowa and Illinois who fear retaliatory tariffs from China.
Why It Matters
The Supreme Court's IEEPA ruling represents the most significant judicial constraint on presidential trade authority since the 1970s, when Congress passed the Trade Act specifically to reclaim some of the tariff-setting power it had delegated to the executive branch. The administration's pivot to Section 232 and 301 is legally more durable but procedurally slower — both statutes require formal investigations and findings before tariffs can be imposed, limiting the president's ability to use tariffs as rapid-response diplomatic tools.
Historically, broad tariff campaigns have produced mixed results. The Smoot-Hawley Tariff Act of 1930 deepened the Great Depression by triggering retaliatory measures from trading partners. The Section 232 steel tariffs of Trump's first term produced some domestic production gains but also raised costs for downstream manufacturers and prompted retaliatory tariffs on US agricultural exports. The current campaign is broader in scope than any previous US tariff action, targeting pharmaceuticals, metals, and potentially dozens of other sectors simultaneously — a scale of trade disruption that has no modern precedent.
What's Next
The Section 301 investigations targeting 60 countries are expected to produce preliminary findings by late summer 2026, with formal tariff recommendations to follow. The EU has already signaled it will challenge the pharmaceutical tariffs at the World Trade Organization and is preparing a list of retaliatory measures targeting US exports of bourbon, motorcycles, and agricultural products — a playbook drawn directly from its 2018 response to the first round of Section 232 steel tariffs. Congress is debating whether to reassert its constitutional tariff authority through legislation, but no bill has advanced out of committee.
Sources: US Treasury; J.P. Morgan; AP News
